A Bioequivalence Study of Domestic (Made in China) and Imported Mizolastine Tablets in Healthy Volunteers

This is a single-center, open-label (all people know the identity of the intervention), randomized (the study medication is assigned by chance), crossover (method used to switch patients from one treatment arm to another in a clinical study) study. Approximately, 24 healthy volunteers will be enrolled in the study. Eligible volunteers will be randomly allocated to either Sequence A group or Sequence B group. On Day 1, volunteers from Sequence A group will receive imported mizolastine tablets and volunteers from Sequence B group will receive domestic mizolastine tablets. There will be a washout period (no treatment) of 7 Days. On Day 8, the two sequence groups will be switched. Volunteers from Sequence A group will receive domestic mizolastine and volunteers from Sequence B group will receive imported mizolastine tablets. Safety evaluations will include assessments of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination, which will be measured throughout the study. The maximum study duration for each volunteer will be approximately 16 days.

Inclusion criteria

• No history of smoking
• Body mass index between 18 and 28 kilogram per square meter
• Health status considered good by the investigator according to physical examination, medical history, vital signs, electrocardiogram and clinical laboratory results
• Must be able to read and understand the informed consent form and sign the informed consent form before carrying out any operation related to the study

Exclusion criteria

• Health examination does not comply with the inclusion criteria
• Serious alcohol abuse
• Known allergy to active ingredients or excipients
• Habitual use of any drug including Chinese medicine